Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Santaolalla, Aida"'
Autor:
Beckmann, Kerri, Santaolalla, Aida, Sugimoto, Mikio, Carroll, Peter, Rubio, Jose, Villers, Arnauld, Bjartell, Anders, Morgan, Todd, Dasgupta, Prokar, Van Hemelrijck, Mieke, Elhage, Oussama, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
Publikováno v:
Prostate cancer and prostatic diseases, vol 26, iss 2
BackgroundCurrently, follow-up protocols are applied equally to men on active surveillance (AS) for prostate cancer (PCa) regardless of findings at their initial follow-up biopsy. To determine whether less intensive follow-up is suitable following ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::9c99680c86f1ed8249c4298ddae8a8e3
https://escholarship.org/uc/item/5dk12186
https://escholarship.org/uc/item/5dk12186
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kerri R, Beckmann, Chris H, Bangma, Jozien, Helleman, Anders, Bjartell, Peter R, Carroll, Todd, Morgan, Daan, Nieboer, Aida, Santaolalla, Bruce J, Trock, Riccardo, Valdagni, Monique J, Roobol
Publikováno v:
Prostate, 82(7), 876-879. Wiley-Liss Inc.
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
2022, ' Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer : An analysis of the G.A.P.3 global consortium database ', Prostate, vol. 82, no. 7, pp. 876-879 . https://doi.org/10.1002/pros.24330
Refereed/Peer-reviewed Background: The optimal interval for repeat biopsy during active surveillance (AS) for prostate cancer is yet to be defined. This study examined whether risk of upgrading (to grade group ≥ 2) or risk of converting to treatmen
Autor:
Kerri Beckmann, Benjamin Challacombe, Sharon Clovis, Oussama Elhage, Christian Brown, Prokar Dasgupta, Aida Santaolalla, Rick Popert, Preeti Sandhu, Paul Cathcart, Mieke Van Hemelrijck, Sohail Singh, Grace Zisengwe, Kamal Dewan, Jonah Rusere
To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance (AS) for prostate cancer (PCa).Men on an AS programme at a single tertiary hospital (London, UK) between 2003 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eb7104cd7401c6841dc2ed705b22fb5
https://hdl.handle.net/11541.2/144947
https://hdl.handle.net/11541.2/144947
Autor:
Rick Popert, Kerri Beckmann, Jonah Rusere, Grace Zisengwe, Aida Santaolalla, Salonee Shah, Oussama Elhage, Mieke Van Hemelrijck, Prokar Dasgupta, Ben Challacombe
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Background The routine clinical use of serum prostatic specific antigen (PSA) testing has allowed earlier detection of low-grade prostate cancer (PCa) with more favourable characteristics, leading to increased acceptance of management by active surve